Effects of Sub therapeutic Doses of ACE-I in Improving insulin sensitivity in Type II DM Patients

Nesren Sh. Mohammed*  Saad A. Hussain*  Isam Noori Ai-Karwi**
*College of Pharmacy,University of Baghdad-Iraq.
** National Center for Diabetes ,Al-Mustansriya university.

Abstract: Diabetes mellitus (DM) is a complex, multifactorial and heterogeneous group of disorders characterized by endogenous insulin deficiency and/or insulin resistance. Regardless of the etiology, the disease manifests itself as a state of chronic hyperglycemia with attendant small blood vessel (microvascular) and large blood vessel (macrovascular) complications. All individuals who have DM have derangement of normal blood glucose and insulin homeostasis. Insulin receptor defects (quantitative and/or qualitative) inhibit glucose uptake by cells as in type 2 diabetes mellitus (T2DM). While Beta cell failure results in inadequate circulating insulin levels as in type 1 diabetes mellitus (T1DM).

30 patients selected with uncontrolled non insulin dependent diabetes mellitus (NIDDM). Their average age was (44.34±7.15) years and their duration of diabetes was 8.48±8.27 years, examination and selection of patients done by the consultant physician ,assistant professor ,at the national center of treatment and research for diabetes. Essential kidney disease and hypertensive patients were excluded, we tested their blood pressure, fasting blood sugar (FBS), post prandial glucose excursion (PPGE) and albuminuria before and after daily captopril intake for 2 months. The results showed a significant decrease (p<0.01) in PPGE (postprandial glucose excursion), after taking angiotensin converting enzyme (ACE) inhibitor captopril mean (185 ±28.75 mg/dl) when compared before captopril intake (230±45 mg/dl) , when calculating the area under the curve. In which these results indicated a positive effect of captopril on insulin sensitivity and blood glucose level.

Keywords: ACE-I, Improving insulin sensitivity, Type II DM Patients

Introduction:
Diabetes mellitus (DM) is a chronic condition that is diagnosed by a blood test and requires lifelong management (1). DM is a complex, multifactorial and heterogeneous group of disorders characterized by endogenous insulin deficiency and/or insulin resistance. While Beta cell failure results in inadequate circulating insulin levels (as in type 1 and type 2) (2). Type 1 DM is characterized by little or no endogenous insulin production. These patients require exogenous insulin, tend to be diagnosed before age 30, Type 2 DM is usually diagnosed after age 30, where a decrease in the number of insulin receptors, or decreased insulin production by chronically stressed pancreatic beta cells. (3)

The glycemic index of the meal depends on the nature of the ingested food and starch composition, thus one of the important test is Postprandial blood glucose excursion (PPGE). In healthy controls, hepatic glucose production is halved after a meal; the nature of the starch was found to be an important determinant of the blood glucose and insulin responses to food giving rise to the concept of glycemic index. (4)

However Insulin sensitivity may be influenced by activity of the renin–angiotensin system (RAS), thus drugs which inhibit the generation of angiotensin II (angiotensin-convertingenzyme inhibitors) may increase hypoglycaemia in diabetes patients (5). It has been shown that treatment with angiotensin converting enzyme inhibitors (ACE-i) and angiotensin receptor blockers (ARB) may improve insulin sensitivity (6) and prevent the development of type 2 diabetes (7,8).

It has also been suggested that blockade of RAS with either ACE-i or ARB increases adiponectin production (9).

Methods

Subjects:
30 patients selected with type 2 DM, (21 male and 9 female) ,during the period that extended from January 2012 to March 2012, their average age was (44.34±7.15) years and their duration of diabetes was (8.48±8.27) years. The diagnostic will done under the consultant physician, assistant profes-
Methods:
First, the patients' sex, age, duration of diabetes, history of smoking, history of another disease or any medication other than hypoglycemic drugs taken and whether they had diabetic retinopathy or not were investigated. Then blood pressure, FBS, PPGE and macroalbuminuria (MAU) were measured. Blood sugar was evaluated spectrophotometrically using a ready made kit for this purpose according to the method of Barham and Trindoer (1972) (10), while the MAU was determined by using a ready made kit according to Mc.Elderry (11).
To make the postprandial glucose excursion (PPGE) (12), the patients were taken their medication to control the blood sugar, and took the basement sample (FBS), then standard meal were given to them that contain 560 Kcal energy, then sample where taken after 30, 60, 90, 120, 170, 210 min. The ACE inhibitor medication was started (captopril 12.5 mg) for 2 months to prove whether it has a hypoglycemic effect or not. The dosage was adjusted according to their blood sugar and blood pressure.

Statistical analysis
The area under the curve concentration was used to see the difference before and after the treatment, in addition to SPSS software (version 13.0 for Windows) to do test on all enumeration data. Also single factor correlation analysis to the clinical parameters was used and then multifactor correlation analysis to parameters was done to get statistical significance after single factor analysis.

Results:
The present study, aimed to examine whether angiotensin converting enzyme inhibitor (ACE) inhibitor, can alter insulin action and if these changes are reflected in interstitial insulin.
Our data show a significant decrease in PPGE (postprandial glucose excursion) level, after taking (ACE) inhibitor captopril mean (185 ±28 mg/dl) then before (230 ±45 mg/dl), when calculated by area under the curve as shown in table (1) and figure (1).
In addition, the data presented in table (1) showed that there is a small non-significant change in FBS after 2 months treatment with placebo from (188.6 ±12 mg/dl) to (191.3 ±22 mg/dl), indicating poor glycemic control of patients using full dose of glibenclamide. While there is a significant reduction in FBS from (192.6 ±3 mg/dl) in patients treated with captopril for 2 months to (145.7±42 mg/dl) (P<0.01), as shown in table (1).
Also a significant decrease (P<0.001) in MAU after 2 months treatment with captopril (231.4 ±21 mg/dl), (174.8 ±15 mg/dl) respectively while no significant change in MAU in placebo, which indicates the efficacy of captopril in improving renal function, as measured by MAU, that shown in table (1).
Discussion:
Our results in this study indicate a positive effect of captopril on insulin sensitivity and glucose metabolism.
Insulin sensitivity may be influenced by activity of the renin–angiotensin system (RAS), although the nature of this relationship remains unclear. Angiotensin II (AI), acting via its G-protein linked receptor, is an important regulator of cardiac, vascular, and renal function. All-induced phosphorylation leads to binding of phosphatidylinositol 3-kinase (PI 3-kinase) to Insulin Receptor Substrate-1 (IRS-1) and Insulin Receptor Substrate-2 (IRS-2); the latter occurs without any reduction in insulin receptor or IRS phosphorylation. These effects of AII are inhibited by angiotensin I (AT1) receptor antagonists. Thus, there is direct cross-talk between insulin and AII signaling pathways at the level of both tyrosine phosphorylation and PI 3-kinase activation. These interactions may play an important role in the association of insulin resistance.
 Patients who start antihypertensive treatment with a captopril-based regimen may be at significantly lower risk for developing diabetes (14), and this is in agreement with our results.
ACE inhibitors have beneficial effects on insulin sensitivity since they have the additional property of decreasing insulin resistance, which can mean improved glycemic control, related to an increase in capillary insulin transport secondary to vasodilatation with increased capillary area is reflected in greater insulin sensitivity and in increased risk of hypoglycemia. Also in this study in patients treated with ACE inhibitors, there was a significant decrease in MAU in placebo, which indicates the efficacy of captopril in improving renal function.
idence of newly diagnosed diabetes by 27% and 23%, respectively (17).

And this is in agreement with Shorr RI (18) who prove that the rate of serious hypoglycemia was highest among those who use an antihypertensives drug of ACE inhibitors. (19, 20, 21)

The reduced incidence of diabetes in patients at high risk of developing diabetes by ACE inhibitors has been explained by hemodynamic effects, such as improved delivery of insulin and glucose to the peripheral skeletal muscle, and non-hemodynamic effects, including direct effects on glucose transport and insulin signaling pathways, all of which decrease insulin resistance. (22) There is now evidence that the pancreas may contain an in situ active RAS, which appears to be up regulated in an animal model of type 2 diabetes. Thus, ACE inhibitors may act by attenuating the deleterious effect of angiotensin II on vasoconstriction, fibrosis, inflammation, apoptosis and [beta]-cell death in the pancreas, thereby protecting a critical [beta]-cell mass essential for insulin production. An evidence is presented that ACE inhibitors may delay or prevent the development of insulin resistance and diabetes (23). And this may be attributed to that captopril improve insulin sensitivity in Type 2 diabetes associated with hypertension at the level of the liver and extrahepatic tissues, primarily muscle and adipose tissue. Thus ACE-inhibitors appear to improve insulin action in Type 2 diabetes. (24)

Table (1): Effect of Treatment with 12.5 mg/day Captopril, on Fasting Serum Glucose (FBS), PPGE and MAU in Type 2 Diabetic Patients.

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>Duration</th>
<th>FBS(mg/dl)</th>
<th>PGEM(g/dl)</th>
<th>MAU(mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>placebo</td>
<td>10</td>
<td>Zero time</td>
<td>188.6 ±12</td>
<td>237 ±21</td>
<td>230.2 ±13</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 months</td>
<td>191.3 ±22</td>
<td>240 ±31</td>
<td>234.6 ±24</td>
</tr>
<tr>
<td>Captopril</td>
<td>20</td>
<td>Zero time</td>
<td>192.6 ±3</td>
<td>230 ±45</td>
<td>231.4 ±21</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 months</td>
<td>145.7 ±42*</td>
<td>185 ±28</td>
<td>174.8 ±15 **</td>
</tr>
</tbody>
</table>

* = significant difference at level p<0.01.
** = significant difference at level p<0.001.

Figure (1): show PPGE before and after the use of captopril drug

References:

2. Stina Lindmark from the Department of Public Health and Clinical Medicine, Mechanisms in Insulin Resistance and Type 2 Diabetes Medicine,Sweden Neurohormonal .2004;67:90-94.

3. HAROLD E. LEBOVITZ, ; Treating hyperglycemia in type 2 diabetes: New goals and strategies CLEVELAND CLINIC


12. Avidon, A, Radance, A, Monnier, L: Non fasting blood glucose is better marker of diabetic control than fasting plasma glucose in type II diabetes ; D.Care :1997;20:1822-1826.


تأثيرات الجرع تحت العلاجية للـ ACE-i في تحسين حساسية الأنسولين
في مرضى السكري من النوع الثاني

نسرين ش. محمد      سعد عبد الرحمن حسين     عصام نوري الكروي

E.mail: dean_coll.science@uoanbar.edu.iq

الخلاصة:

تم اختيار 30 مريض بالنوع الثاني من داء السكري الغير مسيطر عليه وتوزعت اعمارهم بين (44.34 ±7.15) سنوات ومدّتهم من مرض السكر كان (8.48 ±8.27) سنوات. في مركز الابحاث ومعالجة السكري تحت إشراف دكتور اختصاص، تم إبعاد مرضى ضغط الدم وامراض الكلى. تم قياس ضغط الدم ومستوى الكليكوز في الدم وشريحة الكليكوز بعد الأكل، والإيبوبرين بوريا قبل وبعد شهرين من العلاج يوميا بالكايبوبريل. أظهرت النتائج انخفاض معنوي (p<0.01) كبير في شريحة الكليكوز بعد الأكل في المجموعة التي تناولت مادة الكايبوبريل مع الكليكويريد بالمقارنة مع مقبل استخدام الكايبوبريل عند حساب منطقة تحت المنحنى. أظهرت هذه النتائج فعالية الكايبوبريل الأجابة في زيادة حساسية الجسم لفعالية الأنسولين مما يؤدي إلى تحسين السيطرة على مستوى الكليكوز في الدم.